EU - OMC Medical

12Jul 2024

MDCG Guidance on Article 110(3) of the IVDR

MDGC Guidance on significant changes regarding the transitional provision under Article 110(3) of the IVDR aims to provide clarification on the concept of ‘significant changes in the design and intended purpose’. This article applies to manufacturers of devices that comply with Directive 98/79/EC and is placed on the market or put into operation after the transition period ends on May 26, 2022, irrespective of the involvement of notified body under the IVDD. It is important to note that IVDR...

12Jul 2024

EU, FDA, General Information Cubicdesignz Comments: 0

Corrective And Preventive Action (CAPA)

“Corrective action” is the immediate address of an issue, whereas “Preventive action” is addressed to reduce or stop the recurrence of the same error from happening again. What is a CAPA? Corrective And Preventive Action consists of a system of procedures to help improvise the non-conformances, undesirable outcomes and even field safety corrective actions of an organisation. Corrective And Preventive Action must include the following steps: CAPA is a time-bound activity. Corrective And P...

12Jul 2024

EU, EU MDR Cubicdesignz Comments: 0

MEDDEV Guidelines for Clinical Evaluation EU MDR

During the conformity assessment, the manufacturer must submit the complete information material (labelling, IFU (Instructions for Use), any promotional materials and other relevant documents), Clinical evaluation plan & report with the available clinical data, which includes (General Safety and Performance Requirements) GSPR, intended target groups and purpose, qualitative and quantitative aspects of clinical safety, performance procedures and other risk factors involved. The manufacturer m...

12Jul 2024

EU, EU MDR Cubicdesignz Comments: 0

IMDRF guide on Post Market Clinical Follow-up Studies (PMCF)

PMCF is a continuous process that updates the manufacturers’ clinical evaluation during the Post-market surveillance. They must collect user feedback, clinical data, and all other clinical experiences. This article provides an overview of the design, implementation, and appropriate use of PMCF studies. these are an integral part of PMS reports. There may be some data limitations during the premarket phase, like the duration of the investigation and the number of subjects involved or restri...

12Jul 2024

EU, EU MDR Cubicdesignz Comments: 0

EU Notified Body

A notified body is an independent organisation designated by an EU country to assess the conformity of products before being placed on the market. Under EU MDR 2017/745, the notified body is also called a conformity assessment body. A conformity assessment body (CAB) or a notified body is responsible for carrying out the conformity assessment procedure mentioned in the applicable Regulation. What does a notified body do? A notified body assesses whether the product conforms to the require...

12Jul 2024

EU, EU MDR Cubicdesignz Comments: 0

The combination of medical devices and medicinal products based on MDCG 2022-5

This article focuses on the distinctions between the MDD and MDR, considering the terminologies and real-world examples of substance-based devices and combinations of medical and medicinal products. MEDDEV (Medical Devices) 2.1/3 Rev3 guideline for “Borderline products, drug-delivery products, and medical devices incorporating, by an integral part, an ancillary medicinal substance or with ancillary human blood derivative” got replaced with MDCG 2022-5 ” Guidance on the borderli...

EU, EU MDR July 12, 2024 Cubicdesignz Comments: 0

MDCG 2022-16 Guidance for Authorised Representatives (AR)

Article 11 of the Regulation (EU) 2017/745 on medical devices (MDR) and EU Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) outlines the obligations and responsibilities for the Authorised Representatives (AR). Key points are taken for Authorised Representatives in accordance with the guidance:...

12Jul 2024

EU, EU MDR Cubicdesignz Comments: 0

EU MDR Market Surveillance Activities

Market surveillance is the activity carried out by the competent authorities according to Article 93 of MDR 2017/745 to ensure that products on the market comply with the relevant laws and regulations and with the current EU health and safety requirements. Maintaining market security in Europe and promoting consumer safety and business trust is vital. Suppose the medical device poses an unacceptable risk to the health or safety of the patients, users, or other people or any other aspects of the...

12Jul 2024

EU, EU MDR Cubicdesignz Comments: 0

EU IVDR’s First certification for the type of IVD and Notified Bodies Procedures

A short article based on MDCG 2021-22 guidelines on “first certification for the type of devices and the corresponding procedures to be followed by the Notified Bodies, ” established based on Article 106 of Regulation 2017/745 for Class D IVDR devices. Additionally, this guide talks about the conditions to be followed by the Notified bodies, whether to consult the expert panel for the performance evaluation report of the IVDR devices. According to Article 48(6) of IVDR 2017/746, th...

12Jul 2024

EU, EU MDR Cubicdesignz Comments: 0

Vigilance in EU MDR

Introduction The Medical Device Vigilance System’s goal is to lower the risks of using medical equipment and serious incidents while it strives to improve protection for patients, healthcare providers, and other users. A National Competent Authority Report is one way that adverse occurrences are evaluated and, where necessary, information is shared according to the Medical Devices Directives/Regulations (NCAR). The implementation of suitable field safety corrective measures aims to prevent...

Get In Touch:

Get In Touch:

EU

Search

Recent Posts

Categories

Tags

Quick Contact

Opening Hours

Quick Contact

Quick contact

Our Branches

Our Branches

Follow us :

Enquiry Now